Pilot testing in our preclinical trial demonstrated that these tissues have the ability to restore corneal clarity. Additional testing is required to generate the necessary evidence for a Phase I clinical trial with human subjects. The funds obtained through GRIDX will be used to conduct the remaining laboratory tests, allowing us to secure a second round of investment to initiate patient trials.
